1. Going Viral

    Every professional working in the life sciences wants better disease-state education and awareness. The internet has other ideas. Amid the “plague” freakout following the “pneumonia of unknown etiology” in Russia, Dr. Zachary Rubin offers a perspective on how health information now travels:

    This story is almost a perfect example of how medical information gets distorted online. The chain often looks like this:

    Unexplained pneumonia → possible plague → suspected plague → plague case → plague outbreak → “THE PLAGUE IS SPREADING.”

    Those are six very different statements. Yet online, they can collapse into one frightening headline in a matter of hours. Being scientifically literate doesn’t mean dismissing every scary story. It means understanding how much evidence we actually have at each step.

    2. A Golden Age of Neuroscience?

    HLG attended a Brain Economy event at UCLA last week, and one speaker declared we were entering a “golden age of neuroscience.” Just consider the recent Nobel prize for three researchers’ work in optogenetics. One of the winners describes the work:

    “We use light to turn on or off individual cells, or even types of cell or connections from one part of the brain to another. We can turn those on and off with millisecond precision in real time during behaviour, during cognition, and that allows us to see what actually matters for brain function and to start to map function and dysfunction precisely,” said Deisseroth. “It’s a real confluence of engineering and medicine.”

    3. Healthcare’s Next Crisis?

    People are living and working longer than ever. So are doctors. Knowable Magazine explores how healthcare systems are coping with an aging workforce. Solutions are scant. The evidence of a new challenge is not:

    “It’s becoming a bigger issue with each passing year,” says clinical neuropsychologist Victor Del Bene, of the University of Alabama at Birmingham, who has warned of a “looming public health crisis” as an aging physician workforce combines with a persistent undersupply of doctors. Nearly 47 percent of active US physicians are now 55 or older — up from about 38 percent in 2007.

    4. Re-Identified Patient Data

    HIPAA is “the primary statutory vehicle for addressing today’s and tomorrow’s debates on AI in medicine,” according to The American Enterprise Institute. But can it?

    The law is showing its age in ways Congress must confront. HIPAA blesses “de-identified data,” yet modern AI can re-identify patients from supposedly anonymous records. It binds physicians, hospitals, and insurers, but the wearable apps and data brokers that hold and feed algorithms with vast troves of health are not explicitly covered. Indeed, the 1996 law never anticipated the questions of whether patient records may be used to train commercial clinical models at all—or whether patients must be told when an algorithm helps shape their diagnosis or coverage.

    5. Double Play

    Baseball and healthcare are hardly the new chocolate and peanut butter. But for the rare few among us who want to read about both the ballgame and the industry, rejoice. The blog Statcast and Stethoscopes analyzes healthcare through the lens of baseball. It’s not for everyone. But it’s a sure bookmark for some. A sample:

    Pitch tracking technology (like TrackMan or Rapsodo) and high-speed cameras (like Edgertronic) have helped teams get the most out of their pitchers. The camera captures precisely what the hand, fingers, and seams are doing at release, while the tracking system quantifies it (e.g. velocity, spin rates, movement). Motion capture technology and force plates allow teams to precisely measure how efficiently a pitcher generates force through the kinetic chain.

    Medicine hasn’t quite gotten there yet. We’re still pretty far from knowing precisely the threshold where additional antibiotic treatment stops adding benefit and starts adding harm. Now we know it’s probably sooner than we thought. Perhaps we’ll eventually see something like baseball’s pitch design revolution—RCT data on individualized, biomarker-guided, and potentially shorter durations of therapy.